NVS ▼ -3.6% - Novartis AG
$NVS - STAT News - Treatment falls short of Roche’s experimental drug, but has favorable safety profile
23-OCT-2026 12:57 PM ET
Share this post
More filings for $NVS
NVS ▲ +2.4% - Novartis AGOct 7, 2026NVS ▲ +0.3% - Novartis AGSep 9, 2026NVS ▼ -8.0% - Novartis AGSep 4, 2026NVS ▼ -8.0% - Novartis AGSep 4, 2026NVS ▲ +3.5% - Novartis AGSep 1, 2026
View full $NVS filing history →💬 Comments
Loading comments…
Leave a comment